Patents by Inventor Bernd R. Seizinger

Bernd R. Seizinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P53 response genes
    Patent number: 5886149
    Abstract: This present invention concerns polypeptide molecules comprising human p53 response protein PIGI-1.
    Type: Grant
    Filed: November 20, 1996
    Date of Patent: March 23, 1999
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Leonard Buckbinder, Randy Talbott, Bernd R. Seizinger, Nikolai Kley
  • NF2 isoforms
    Patent number: 5872214
    Abstract: Novel human and mouse NF2 transcript isoforms and proteins encoded thereby, are disclosed. The isoforms are found in a variety of tissue and tumor types and represent differential processing of genomic DNA sequences, at the level of transcription, resulting in variant proteins. The isoforms provide useful tools for the analysis of the normal function of tumor suppressor factors, such as the merlin protein, and also provide useful markers for the detection of NF2 disease.
    Type: Grant
    Filed: April 4, 1996
    Date of Patent: February 16, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bernd R. Seizinger, Nikolai A. Kley, Albert B. Bianchi
  • Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of p53-related tumors
    Patent number: 5840673
    Abstract: Methods of treating p53-related tumors by administering (1) a modulator of IGF-BP3, wherein the modulator upregulates IGF-BP3 expression or activity, (2) IGF-BP3 itself, or (3) an expression vector comprising a nucleotide sequence encoding IGF-BP3. In the latter method, the IGF-BP3 nucleotide sequence may also be operatively linked to an inducible promoter or enhancer, wherein the method further comprises administering an inducer capable of initiating or upregulating expression of the protein. Furthermore, any of the foregoing methods may include as an additional step administration of a cytotoxic agent. These methods are specific examples of a broader method: treatment of p53-related tumors by inhibiting the binding of IGF to IGFR.
    Type: Grant
    Filed: September 12, 1996
    Date of Patent: November 24, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leonard R. Buckbinder, Nikolai Kley, Bernd R. Seizinger
  • P53 response genes
    Patent number: 5667987
    Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of p53 response protein PIGI-1, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials are disclosed. The invention also concerns polypeptide molecules comprising all or part of p53 response protein PIGI-1, and methods for producing these polypeptide molecules.
    Type: Grant
    Filed: July 12, 1994
    Date of Patent: September 16, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leonard Buckbinder, Randy Talbott, Bernd R. Seizinger, Nikolai Kley
  • NF2 isoforms
    Patent number: 5578462
    Abstract: Novel human and mouse NF2 transcript isoforms and proteins encoded thereby, are disclosed. The isoforms are found in a variety of tissue and tumor types and represent differential processing of genomic DNA sequences, at the level of transcription, resulting in variant proteins. The isoforms provide useful tools for the analysis of the normal function of tumor suppressor factors, such as the merlin protein, and also provide useful markers for the detection of NF2 disease.
    Type: Grant
    Filed: January 10, 1994
    Date of Patent: November 26, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bernd R. Seizinger, Nikolai A. Kley, Albert B. Bianchi